ProPhase Labs Inc. (PRPH)
NASDAQ: PRPH
· Real-Time Price · USD
0.43
-0.09 (-16.52%)
At close: Sep 12, 2025, 3:59 PM
-16.52% (1D)
| Bid | 0.42 |
| Market Cap | 18.01M |
| Revenue (ttm) | 3.34M |
| Net Income (ttm) | -41.45M |
| EPS (ttm) | -2.07 |
| PE Ratio (ttm) | -0.21 |
| Forward PE | 0.33 |
| Analyst | n/a |
| Dividends | n/a |
| Ask | 0.47 |
| Volume | 5,509,330 |
| Avg. Volume (20D) | 7,118,587 |
| Open | 0.50 |
| Previous Close | 0.52 |
| Day's Range | 0.42 - 0.51 |
| 52-Week Range | 0.22 - 2.83 |
| Beta | -0.77 |
| Ex-Dividend Date | n/a |
About PRPH
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PRPH
Website n/a
ProPhase Labs Inc. is scheduled to release its earnings on
Nov 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
-15.84%
ProPhase Labs shares are trading lower. The compan...
Unlock content with
Pro Subscription
1 month ago
+25.67%
ProPhase Labs shares are trading higher after the company announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12379378-B2 for its biomarker-based systems and methods to assess progression risk in Barrett's esophagus and esophageal adenocarcinoma.
